about
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisAnti-angiogenesis and metastasis: a tumour and stromal cell allianceThe p21(Cip1) protein, a cyclin inhibitor, regulates the levels and the intracellular localization of CDC25A in mice regenerating liversNotch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signallingDrug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsFilamin B plays a key role in vascular endothelial growth factor-induced endothelial cell motility through its interaction with Rac-1 and Vav-2.PTEN mediates Notch-dependent stalk cell arrest in angiogenesisStem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing.Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors.Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in miceExploiting pleiotropic activities of semaphorins as multi-target therapies for cancerDeficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic disseminationNew drug development in digestive neuroendocrine tumors.MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes.The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtypeRelevance of angiogenesis in neuroendocrine tumors.Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.Antiangiogenic therapies: going beyond their limits.Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.Scanning, non-contact, hybrid broadband diffuse optical spectroscopy and diffuse correlation spectroscopy systemTranslational research in neuroendocrine tumors: pitfalls and opportunities.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis.Angiogenesis and Metabolism: Entwined for Therapy Resistance.Non-invasive monitoring of hypoxia-inducible factor activation by optical imaging during antiangiogenic treatment in a xenograft model of ovarian carcinoma.Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine TumorsResistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.P38SAPK2 phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation.Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner.Antiangiogenic resistance via metabolic symbiosis.Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).The use of caspase inhibitors in pulsed-field gel electrophoresis may improve the estimation of radiation-induced DNA repair and apoptosis.The adaptive stroma joining the antiangiogenic resistance front.Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis.
P50
Q24608039-3A750E05-85BF-4A8A-A0EA-E88F1DE7E5B6Q26862741-8FD94F5F-CEC1-4B2C-A6AC-1B45B0C03D70Q28509509-A38C6FF5-0F0E-4792-AAD9-8BB5DD0BFBFAQ28587298-E97D7591-ECB2-442A-901E-8168C5F56CF7Q29615445-EBFBFA79-427D-42AB-B310-DABD3CDF43E2Q30494138-DF10CA1E-583F-435F-A4CD-B775407425ECQ33663049-A5BCFFA7-BF9E-45E5-B935-DFEEA43D3194Q33721249-E06E7CB1-F232-45A0-9D55-CE8580EDF5EDQ33824587-E0C2BACC-D0BC-4A96-A208-8169B786019FQ33835075-9CAB988E-A83C-4FA2-B004-20047D232BD6Q34928941-56707969-42D3-4EDA-A9A9-800FBA1B23F8Q35913662-023E0FC4-3D87-4A85-B5C0-CB3EE5CF7064Q36037962-09DB66AC-A8F8-4095-A6DB-4DAC7BE3C6B2Q36694132-992BA0A0-56C6-47B2-969C-25D34A15A2A3Q36735939-A45A6528-701D-4642-AAB3-8C8C410DCB85Q36962575-77C67462-3983-41CB-B8D6-C023EEF114C8Q37644995-3247517B-E3FF-4A39-ADC3-1DBF3953E18FQ37710826-8AA04C0F-C409-4E5B-A605-1156EE14E939Q38010658-8C412320-9E93-4094-A969-6EBA3DCA1828Q38086427-BFA3136A-1030-4CA1-956B-8253D960935CQ38172781-899D81DE-99D4-46DD-8CD3-67E1DC2B6EFCQ38174516-CB2DC19B-B067-4B63-B18F-ED47A872285CQ38681603-A5E161FF-76EC-4DF8-9850-C63F528C62BCQ38958002-654EE303-7C54-42D9-A909-CB079FC25312Q39008859-FCA81B7F-5D3D-4EB7-9752-7500EBBF970EQ39054795-404B14BA-5482-4E2D-B401-579AD189F219Q39094806-7E5311BB-3467-4E36-84A4-13E5A31EA02BQ39441308-29CA0B01-ACFE-4B11-AB51-D3361DD0B9C9Q39525848-9ECB5A9B-C9C8-416C-BA7C-FC0F27B26597Q39547351-11636581-4C73-4D66-A420-278F25BA8C1AQ39735943-8F24CE68-C399-47D4-B2F4-0213B6766796Q39805218-E752FC5B-C1E9-4563-8A07-B578F9B32956Q39856473-ECADD402-2957-4F9F-9561-47ADBE9A41EBQ40522877-B40671FF-9A04-4948-A972-706EBEC1B75FQ40859800-C3E54678-6FCE-45F1-93F1-BC004C3D1D55Q41487795-7DF99C31-6F2F-41D6-A8B5-5D6B99E8872BQ41679292-93076F42-E518-4FF4-81FD-A4A311977790Q41954705-7581A283-8BD3-4444-AB80-63AB1B7A49B7Q42125857-BB0B6046-E35F-4A5E-BC39-A59DBD83AB26Q42512142-B90E6C87-10E8-405F-9DEA-7CBAA0F2D859
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Oriol Casanovas
@ast
Oriol Casanovas
@en
Oriol Casanovas
@es
Oriol Casanovas
@nl
type
label
Oriol Casanovas
@ast
Oriol Casanovas
@en
Oriol Casanovas
@es
Oriol Casanovas
@nl
altLabel
O Casanovas
@en
prefLabel
Oriol Casanovas
@ast
Oriol Casanovas
@en
Oriol Casanovas
@es
Oriol Casanovas
@nl
P1053
L-5210-2014
P106
P1153
6603249696
P21
P31
P3829
P496
0000-0002-4298-3995